Targeting EEF1A2 with plitidepsin and cancer-specific pathway inhibitors [check https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/approved-drug-list for US Food and Drug Administration (FDA)-approved targeted therapy drugs] may provide a synergistic effect to inhibit cell survival and proliferation. This evidence concerns the gene EEF1A2 and cancer.